Self-assembled nanofibers as hemostatic agents

By developing casein and chitosan nanofiber polyelectrolyte complexes, the efficiency and cost problems of existing hemostasis agents are solved, and a rapid and safe hemostasis effect is achieved, which is suitable for a variety of wound conditions.

CN113747901BActive Publication Date: 2024-12-06NAT INST OF TECH ROURKELA
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202080029543.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-04-18
Filing Date
2020-04-17
Publication Date
2024-12-06
Estimated Expiration
2040-04-17

AI Technical Summary

Technical Problem

Existing hemostatic agents have defects in efficiency and cost, such as QuickClotTM causing temperature rise, HemconTM cost high, XStat may cause foreign body reactions, and fibrin based on animals or humans has the risk of immunogenicity and viral contamination, which is difficult to in emergencies. Used under.

Method used

A nanofiber polyelectrolyte complex containing casein or its derivative and chitosan or its derivative is developed to prepare nanofibers with a diameter in the range of 20-200 nm by self-assembly method to promote rapid hemostasis.

Benefits of technology

It achieves coagulation within 20 seconds, stops bleeding almost instantly, and is biocompatible and degradable, avoids side effects, and the preparation method is easy to expand production, and is suitable for various wound conditions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113747901B_ABST
    Figure CN113747901B_ABST
Patent Text Reader

Abstract

The present disclosure provides a composition comprising: a polyanionic component comprising casein or a derivative thereof; and a polycationic component comprising chitosan or a derivative thereof, wherein the composition is in the form of nanofibers having a diameter in the range of 20-200 nm. The present disclosure also discloses a method for preparing the composition and a hemostatic product comprising the composition of the present disclosure. In addition, the present invention also discloses a method for inhibiting blood loss from a bleeding site, and uses of the composition and the hemostatic product.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The subject matter described herein relates generally to the field of polyelectrolytes, and particularly to a composition for inhibiting excessive blood loss from a bleeding site. Background Art

[0002] Excessive blood loss is one of the main causes of death for soldiers and civilians. In addition to major organ damage, many people die simply from excessive blood loss. According to doctors, almost 80% of soldiers die within half an hour of being injured due to massive blood loss. The same is true for civilians. About 50% of accident victims die before receiving proper treatment simply due to massive blood loss (Heiskell et al., Blood clotters, Police Maagzine, 2004). Therefore, research efforts to promote the suppression of excessive blood loss in a shorter period of time is a boon to solving this related problem.

[0003] Blood has its own complex clotting process consisting of unique extrinsic and intrinsic pathways. Therefore, whenever there is a small cut, the blood will clot on its own and prevent further bleeding, but in case of a deep cut, the blood will not clot on its own. Due to this problem, there should be an external component that can help the self-clotting mechanism of the blood and promote rapid hemostasis, thereby preventing blood loss.

[0004] Several different forms of materials have been studied to effectively control bleeding. In fact, there are already various materials available in the market, but most of these materials have their own drawbacks in terms of their efficiency and price. For example, QuickClot TM Inducing a temperature rise upon application, Hemcon TM The cost of XStat is very high, while XStat can cause a foreign body reaction if left in the body. In addition, the high cost of most of these coagulants is another disadvantage that hinders their widespread use.

[0005] Absorbent biomaterials impart partial hemostasis by simply absorbing blood and exudate. Cellulose, oxidized cellulose, oxidized regenerated cellulose, and starch-based bandages all fall into this category. Various products based on the absorption mechanism have been developed, such as HaemoCer TM Plus TM Arista TM 、PerClot TM and Starsil Hemostatic Powders TM . Starch-based fast swelling porous superabsorbent hydrogel (FSPSH) has also been reported (J Biomater Sci Polym Ed. 2015; 26: 1439-1451). RevMedxTM X-Stat TM It is based on an absorption mechanism (J Spec Oper Med. 2016; 16:19-28). It has been developed for deep wounds, such as gunshot wounds. However, since it is based on wood pulp, it may cause a severe foreign body reaction if left in the body.

[0006] Since fibrin plays a vital role in the formation of a stable clot, fibrin, fibrinogen, and thrombin have been used for hemostatic effects. Fibrin-based dressings have shown superior hemostatic properties compared to absorbent dressings (J Trauma Inj Infect Crit Care. 2008; 64: 75-80). TM and TachoSil TM Products are several examples of fibrin-based hemostatic agents.

[0007] In recent years, efforts have also been made to develop recombinant forms of this coagulation protein (Clin Ther. 2009; 31: 32-41). One such example is the clinically approved Recothrom TM , which is a fully recombinant human thrombin (Nat Biotechnol. 2008; 26: 250-250). Fibrin dressings have great potential to reduce mortality.

[0008] Considering the current situation, there are challenges associated with readily available cost-effective coagulants. In addition, fibrin derived from animal (cow, pig) or human mixed blood brings the additional risk of immunogenicity and viral contamination. In addition, these bandages cannot be used in emergency situations due to the need for reconstitution before application.

[0009] Therefore, there is an urgent need for a bleeding control agent that is cost-effective, easily available, has a low risk of immunogenicity, is free of viral contamination, and can be used in emergency situations. Summary of the invention

[0010] In one aspect of the present disclosure, a composition is provided, comprising: (a) a polyanionic component comprising casein or a derivative thereof; and (b) a polycationic component comprising chitosan or a derivative thereof, wherein the composition is in the form of nanofibers having a diameter in the range of 20-200 nm.

[0011] In a second aspect of the present disclosure, a method for preparing a composition is provided, the composition comprising: (i) a polyanionic component comprising casein or a derivative thereof; and (ii) a polycationic component comprising chitosan or a derivative thereof, wherein the composition is in the form of nanofibers having a diameter in the range of 20-200 nm, the method comprising: (a) contacting a first aqueous solution of the polyanionic component comprising casein or a derivative thereof with a second aqueous solution of the polycationic component comprising chitosan or a derivative thereof to obtain an aqueous mixture; (b) treating the aqueous mixture to obtain suspended particles; (c) contacting the suspended particles with a desolvating agent to obtain a suspension; and (d) drying the suspension to obtain the composition.

[0012] In a third aspect of the present disclosure, there is provided a hemostatic product comprising a composition comprising: (a) a polyanionic component comprising casein or a derivative thereof; and (b) a polycationic component comprising chitosan or a derivative thereof, wherein the composition is in the form of nanofibers having a diameter in the range of 20-200 nm.

[0013] In a fourth aspect of the present disclosure, a method for inhibiting blood loss from a bleeding site is provided, the method comprising: (a) obtaining a composition as described herein or a hemostatic product as described herein; and (b) applying the composition to a bleeding site to inhibit blood loss from the bleeding site.

[0014] In a fifth aspect of the present disclosure, there is provided a use of the composition for inhibiting blood loss from a bleeding site, the composition comprising: (i) a polyanionic component comprising casein or a derivative thereof; and (ii) a polycationic component comprising chitosan or a derivative thereof, wherein the composition is in the form of nanofibers having a diameter in the range of 20-200 nm.

[0015] In a sixth aspect of the present disclosure, there is provided a hemostatic article comprising a composition for inhibiting blood loss from a bleeding site, the composition comprising: (i) a polyanionic component comprising casein or a derivative thereof; and (ii) a polycationic component comprising chitosan or a derivative thereof, wherein the composition is in the form of nanofibers having a diameter in the range of 20-200 nm.

[0016] These and other features, aspects and advantages of the subject matter of the present invention will be better understood with reference to the following description and the appended claims. This summary is provided to introduce some concepts in a simplified form. This summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used to limit the scope of the claimed subject matter. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] The detailed description is described with reference to the accompanying drawings. The same numerals are used throughout the specification to refer to similar features and components of the different drawings.

[0018] Figure 1 The process steps for preparing a composition according to an embodiment of the present disclosure are shown.

[0019] Figure 2 FE-SEM images of the compositions of the present disclosure at lower and higher magnifications, respectively, are shown, indicating the diameter of the nanofibers, wherein the compositions have casein and chitosan in a weight ratio of 30:70 (CA30CH70 PEC powder) (A, B), casein and chitosan in a weight ratio of 50:50 (CA50CH50 powder) (C, D), and casein and chitosan in a weight ratio of 70:30 (CA70CH30 powder) (E, F), respectively, according to embodiments of the present disclosure.

[0020] Figure 3 Surface charges of CA30 CH70, CA50 CH50, and CA70 CH30 are shown according to embodiments of the present disclosure.

[0021] Figure 4 Shown are FE-SEM images of blood clots treated with PEC powder samples of CA30CH70 (A, B), CA50CH50 (C, D), and CA70CH30 (E, F) at lower and higher magnifications, respectively, according to one embodiment of the present disclosure.

[0022] Figure 5 The LDH activities of CA30CH70, CA50CH50, CA70CH30, and Celox according to embodiments of the present disclosure are shown.

[0023] Figure 6 Prothrombin times for CA30CH70, CA50CH50, CA70CH30, and Celox according to embodiments of the present disclosure are shown. DETAILED DESCRIPTION

[0024] Those skilled in the art will appreciate that the present disclosure may also be subject to variations and modifications other than those specifically described. It should be understood that the present disclosure includes all such variations and modifications. The present disclosure also includes all such steps, features, compositions and compounds mentioned or indicated in this specification, either individually or collectively, and any and all combinations of any or more such steps or features.

[0025] For convenience, certain terms used in the specification and examples are described herein before further describing the present disclosure. These definitions should be read in light of the remainder of the present disclosure and understood by those skilled in the art. The terms used herein have meanings recognized and known by those skilled in the art, however, for convenience and completeness, specific terms and their meanings are set forth below.

[0026] The articles "a," "an," and "an" are used to refer to one or more than one (ie, to at least one) of the grammatical object of the article.

[0027] The terms "comprising" and "including" are used in an inclusive, open sense, meaning that additional elements may be included. It is not intended to be interpreted as "consisting only of. . . . . .

[0028] Throughout the specification, unless the context requires otherwise, the word “comprise” and variations such as “comprising”, will be understood to imply the inclusion of stated elements or steps or groups of elements or steps but not the exclusion of any other elements or steps or groups of elements or steps.

[0029] The term "including" is used to mean "including but not limited to." "Including" and "including but not limited to" are used interchangeably.

[0030] Ratios, concentrations, amounts and other numerical data may be presented in range format herein. It should be understood that such range format is used only for convenience and brevity, and should be flexibly interpreted as including not only the values ​​explicitly stated as the upper and lower limits of the range, but also all individual values ​​or sub-ranges contained within the range, as if each value and sub-range were explicitly stated. For example, a diameter range of 20-200 should be interpreted as including 30 and 76, and also including sub-ranges such as 35-93, 21-64, 35-90, etc.

[0031] The term "at least one" is used to mean one or more than one, and thus includes individual components as well as mixtures / combinations.

[0032] The term "nanofiber" refers to fibers having a diameter in the nanometer range.

[0033] The term "polyelectrolyte complex" or "PEC" describes a complex formed between two polymers, wherein at least one of the polymers is polycationic and the other polymer is polyanionic.

[0034] The term "wound site" or "wound" describes any site on the body of any animal or human that is injured or has undergone physical trauma that results in blood loss. The present disclosure is intended to cover the application of the compositions (nanofibers) as described herein to wound sites of any animal or human or any living organism that requires any kind of intervention to stop blood loss.

[0035] The term "hemocompatibility" describes the compatibility of erythrocytes or blood with any substrate, or in the present case with PECs.

[0036] The terms "antimicrobial agents, growth factors, anti-inflammatory agents, antihistamines, compounds containing copper or silver ions" are used to describe a broad class of well-known ingredients known to those skilled in the art.

[0037] The term "haemorrhaging" refers to excessive blood loss. If excessive blood loss occurs at a site, the site is called a bleeding site.

[0038] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art to which the present disclosure belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference.

[0039] The present disclosure is not to be limited in scope by the specific embodiments described herein, which are intended for illustrative purposes only. As described herein, functionally equivalent products, compositions and methods are clearly within the scope of the present disclosure.

[0040] In order to solve the problems associated with existing hemostatic agents, the present disclosure provides a composition, which is a nanofiber polyelectrolyte complex comprising casein and chitosan. The composition is a self-assembled reconstructed nanofiber polyelectrolyte complex that promotes effective hemostasis. According to the present disclosure, the composition (nanofiber PEC) has been manufactured by a self-assembly process, and the composition has been determined to be a suitable hemostatic agent. Nanofibers are generally manufactured using phase separation, self-assembly and electrospinning. Among these technologies, electrospinning has become the most preferred method because various polymer arrays can be used to manufacture nanofibers. However, the entangled fiber structure of the electrospun pad limits their use in powder form for hemostatic applications. Another challenge of the electrospinning method is to achieve high throughput. In the present disclosure, short nanofibers with different surface charges have been manufactured using a self-assembly method. This method allows the production of nanofiber powders, which can be easily scaled up for commercial purposes.

[0041] The present disclosure provides the development of a bleeding control agent consisting of a polycationic polymer and a protein (in polyanionic form), which results in the formation of nanofibers having an average fiber diameter of less than 200 nanometers, wherein these nanofibers have been developed by a self-assembly method that produces very high yields and is easily converted to industrial production. The compositions disclosed in the present disclosure have several applications, i.e., controlling bleeding caused by any type of accident, surgery, or the body's own physiology. The compositions are also very effective in cases of gunshot wounds, knife wounds, clinical wounds, postoperative incisions, wound dressings, etc., directly as powders, patches, gels, or bandages. In addition, the compositions can be used as wound dressing materials, coatings for medical implants and devices, and in combination with bandages.

[0042] The composition disclosed in the present disclosure provides a nanofiber powder with a fiber diameter in the range of 20-200 nm. It can make fatal injuries coagulate within 20 seconds and almost instantly stop bleeding in surface tears, distortions, incisions, etc. The present disclosure also provides a method for manufacturing the above-mentioned biomaterial that has been completed by a self-assembly method.

[0043] The disclosed composition (nanofiber polyelectrolyte complex) can be manufactured by preparing a stock solution of a polycationic biomaterial (e.g., gelatin, dextran, chitin or cyclodextrin in deacetylated form) and a polyanionic biomaterial (e.g., hyaluronic acid, alginate, casein, dextran sulfate, carrageenan, chondroitin sulfate, pectin, polygalacturonic acid, xanthan gum, heparin or their sodium or potassium or calcium salts or derivatives) at room temperature (e.g., 20-25° C.). The stock solutions of the main components are mixed together in the desired weight ratio. The mixture of the main components is washed with an organic solvent having a low surface tension, such as methanol, ethanol, tert-butyl alcohol, acetone or hexane instead of water. The organic solvent is then evaporated by rapid drying on a hot surface to produce a nanofiber polycationic complex with a diameter in the range of 20-200 nanometers. The polycationic biomaterial and the polyanionic biomaterial can be mixed in a weight ratio in the range of 8:2 to 2:8. Polycationic biomaterials, such as gelatin, dextran, chitin or cyclodextrin in deacetylated form or their derivatives, can be obtained from various commercial sources, including, but not limited to, for example, the following sources: Sigma-Aldrich (MO, USA), Hi-Media (Mumbai, India) and Loba Chemie (Mumbai, India). Gelatin, dextran, chitin or cyclodextrin in deacetylated form or their derivatives can be used as polycations, such as derivatives in which the acetylation percentage is changed or the polymer length is shortened for the purpose of changing solubility or other physicochemical properties. Natural polyanions can be used, such as casein, hyaluronic acid, alginate, dextran sulfate, carrageenan, chondroitin sulfate, pectin, polygalacturonic acid, xanthan gum, heparin or their sodium salts or potassium salts or calcium salts. Antimicrobial agents, growth factors, debridement agents, etc. can also be added to the prepared nanofiber polyelectrolyte complex to develop wound dressings with hemostatic properties. Therefore, it should be well understood that some of the features mentioned herein can be used in combination with any other features of the prior art. However, the specific embodiments disclosed herein are in fact preferred embodiments of the invention. These features are not indispensable or essential.

[0044] The present disclosure encompasses the preparation of compositions (nanofiber polyelectrolyte complex powders) having a diameter of less than 100 nanometers and capable of rapid coagulation in less than 20 seconds in the case of any kind of fatal injury ranging from shallow to deep wounds and minor to severe injuries, and almost instantaneous in the case of rise due to medical reasons. In the case of trauma caused by gunshots, stabbings, accidental trauma, car accidents, etc., the present disclosure helps the victim have a chance to reach the point of care without losing a fatal amount of blood. In the case of injuries that lead to severe bleeding, the use of such bleeding control agents (hemostatic agents) as described herein will be highly beneficial.

[0045] The disclosed composition (nanofiber polyelectrolyte complex) is biocompatible, biodegradable, and when applied to a bleeding surface (e.g., a wound), it absorbs large amounts of fluid and causes blood clots without causing excessive dehydration of the wound site. Polyelectrolytes are macromolecules that exhibit a net positive or negative charge when dissolved in a polar solvent such as water at a specific pH. When oppositely charged polyelectrolytes come into contact with each other, they form polyelectrolyte complexes or otherwise known as polysalts. The driving force for the formation of polyelectrolyte complexes is the entropy and strong electrostatic attraction between oppositely charged polymers. When negatively charged groups approach positively charged groups, they begin to attract each other and form an ionically crosslinked material. Crosslinking refers to the bond that connects one polymer chain to another polymer. In the presence of some crosslinking agents, negative functional groups from the same or different chains are attracted toward positively charged functional groups. This crosslinking phenomenon also depends on pH. For example, in the present embodiment, nanofibers can only be formed when the pH of the complex is maintained within a range suitable for nanofiber formation. Above a specific pH value, fiber formation becomes less and more particle formation occurs. When this cross-linking compound comes into contact with blood, it forces the blood cells to bind or become captured on the surface of the substrate, thereby helping them to form a network that leads to strong plaque formation.

[0046] According to an embodiment in the embodiments, two biomaterial stock solutions are mixed together. Polycations, such as chitin in deacetylated form and polyanions, such as casein, are used as the main components for forming nanofiber polyelectrolyte complexes. The formation of complex is spontaneous and is accompanied by the release of counterions. The process is completely based on water and does not require any toxic solvents.

[0047] Once the polyelectrolyte complex is formed, a water replacing agent (desolvating agent) is introduced in the next step of the manufacturing method. This water replacing agent plays a key role in developing a dry nanofiber polyelectrolyte complex powder. In a preferred embodiment, it allows the nanofibers not to aggregate together to form agglomerates. When the water molecules are completely replaced by the reagent and heated, the above reagent evaporates, leaving nanopores and fiber structures, which in turn increases the surface-to-volume ratio of the nanofibers. This increased surface-to-volume ratio leads to higher absorption properties of the nanofiber sample. In this article, the prepared polyelectrolyte complex (composition of the present disclosure) is washed with an organic solvent (desolvating agent) with low surface tension, such as methanol, ethanol, butanol, acetone or hexane to replace the water molecules, which later helps to produce pores and fiber structures during the drying process. According to the present disclosure, tert-butyl alcohol provides the best results, and the resulting final fiber complex shows a nanostructure with a fiber diameter of less than 200nm.

[0048] Polycationic biomaterials may be used, including but not limited to gelatin, dextran, deacetylated forms of chitin, cyclodextrin or poly-L-lysine. In the present disclosure, deacetylated forms of chitin (chitosan) gave the best results.

[0049] Polyanionic biomaterials can be used, including but not limited to casein, hyaluronic acid, alginate, dextran sulfate, carrageenan, chondroitin sulfate, pectin, polygalacturonic acid, xanthan gum, heparin or their sodium or potassium or calcium salts. In the present disclosure, casein has been used and it gives the best results.

[0050] The disclosed composition (nanofiber polyelectrolyte complex) can be made into powder form, gel form or liquid form. In addition, the present disclosure is not limited to polyelectrolyte complexes consisting only of polysaccharides and proteins, and other hemostatic agents such as biological hemostatic agents, bioactive glass, molecular sieve materials, thrombin, fibrin, other similar materials or the combination of the foregoing with the present embodiment are also within the scope of the present disclosure.

[0051] Any other clay particles or other coagulants or materials of some embodiments can be added together with the present embodiment, or can be used in combination, which can lead to the efficacy of the composition of the present disclosure being improved. Some embodiments in the embodiment may involve adding or integrating several materials into the present disclosure, for maintaining or improving the sterile environment at the injured area. For example, anti-inflammatory agents, antifungal agents, antibiotics, antihistamines, antimicrobial agents, silver ions or copper-containing compounds, combinations of the above and similar other materials can be used. In addition, some different materials can be merged with the present embodiment to incorporate pain relief properties into the present embodiment. According to the nature of the injury, biological hemostatic materials, such as human serum albumin, bovine thrombin, calcium, human thrombin (h thrombin), rh thrombin, factor XIII, factor VIIa, recombinant factor XIII (r factor XIII), prostaglandin-2a, thromboxane A2, epidermal growth factor, tumor necrosis factor (TNF), platelet-derived growth factor, TNF-α, transforming growth factor (transforming growth factor, TGF), von Willebrand factor (Von Willebrand factor), TGF-α, TGF-β, fibroblast growth factor, nerve growth factor, insulin-like growth factor, keratinocyte growth factor, penicillin, methicillin, ampicillin, amoxicillin, clavulanic acid, clavamox, aztreonam, streptomycin, imipenem, kanamycin, bacitracin, tobramycin, vancomycin, polymyxin, gentamicin, clindamycin, erythromycin, amphotericin, rifampicin, nystatin, tetracycline, doxycycline, doxycycline, chloramphenicol, fibrin, thrombin, ascorbic acid, rutin, tranexamic acid, combinations of the above or similar materials can be used in this embodiment to provide additional hemostatic function. In addition, plant-derived agents having a desired effect at the wound site can be used in the present embodiment, and for example, Glycyrrhiza glabra, Thymus vulgaris, Alpinia officinarum, Vitis vinifera, Urtica dioica, Newbouldia laevis (leaves), Annona senegalensis (leaves), Cissampelos mucronata (aerial parts), Cassytha filiformis (aerial parts), etc. can be used.

[0052] The material used for water replacement in the present disclosure may also be some other different alcohols. The water replacement material may be any other single alcohol, a mixture of more than one alcohol, a mixture of water and alcohol, or a combination of the above substances. After repeated washing with ethanol, the polyelectrolyte complex and the ethanol suspension are dried at a temperature within 70° C. to 110° C., which results in the formation of nanofiber material. The present disclosure is not limited in this respect, and other nanofiber preparation methods with an average fiber diameter within 100 nanometers are also within the scope of this embodiment.

[0053] Several types of materials and different combinations thereof can be used to realize the compositions of the present disclosure. The materials can be fibrous, composed of single or multiple fibers, such as: sutures or ropes; meshes; gazes; woven or nonwoven; absorbent or non-absorbent; tightly woven textiles; porous or solid; sponges, etc. In some embodiments, the aforementioned combinations can be used, and they can be connected to each other in different ways. In some embodiments, the fibers can also be coated with one or more additives for improvement.

[0054] In some embodiments, several salts may be combined with a polyelectrolyte complex (eg, calcium chloride, sodium tripolyphosphate, salts of the same type, or combinations thereof).

[0055] Finally, in order to obtain the product, different ways can be obtained. In some embodiments, a special dryer can be used for drying to obtain the final product. A special dryer refers to a commercially available dryer, such as a spray dryer, a vacuum dryer, a drum dryer or a similar type of machine, to solve the drying purpose or the above combination. In some embodiments, the final product can be achieved in two steps, i.e., drying the substrate, and converting the dried substrate into the desired form after drying. Drying can be achieved in several ways: this includes increasing the temperature of the air around the substrate so that the water replacement agent is completely evaporated. In some embodiments, the substrate can be directly heated by any means. In some embodiments, a freeze-drying process can be used for drying purposes. Drying parameters such as temperature, vacuum level, duration and / or pressure can be changed or adjusted to produce the product. Converting the dried substrate into the desired form can be achieved in different ways. In some embodiments, crushing or grinding of the dried substrate can be performed, or other methods of similar types that will not significantly reduce the efficacy of the substrate can be obtained. In some embodiments, heating and grinding can be performed simultaneously.

[0056] In the present disclosure, the disclosed hemostats have very high absorption capacity for one or more liquids such as water, blood, etc. In some embodiments, the substrate may have an absorption capacity of at least 4 to 10 times or even more times its original dry weight.

[0057] In order to demonstrate the ability of the composition described in the present disclosure, the composition was characterized using FESEM (field emission scanningelectrom microscope). The coagulation ability of the substrate described in the present embodiment was evaluated using whole blood coagulation assay. In the present embodiment, in order to ensure the cell adhesion ability of the substrate, blood with the substrate was queried using FESEM. The present disclosure also includes the ability of the substrate to withstand the blood pressure at the injury site. This means that the substrate will remain at the application site of the injured area after application and will not be washed away by the blood flow. It will form a hard plaque there, resulting in no further bleeding.

[0058] The disclosed nanofiber polyelectrolyte complexes can generally be placed in suitable sealed packaging (e.g., a pouch or vial made of suitable material, or a kit comprising such packaging and optionally printed instructions for use), and sterilized prior to further packaging, if desired, with printed instructions for use describing the proper use of the material or kit in the treatment of bleeding. Suitable sterilization methods include ionizing radiation (e.g., gamma radiation) or ethanol treatment.

[0059] The disclosed nanofiber polyelectrolyte complexes can be applied directly (e.g., to clean wounds) or as part of a multi-step treatment regimen (e.g., to infected wounds). The multi-step treatment regimen can include or be followed by a cleaning and disinfection step followed by application of the disclosed nanofiber polyelectrolyte complexes.

[0060] In an embodiment of the present disclosure, a composition is provided, comprising: (a) a polyanionic component comprising casein or a derivative thereof; and (b) a polycationic component comprising chitosan or a derivative thereof, wherein the composition is in the form of nanofibers having a diameter in the range of 20-200 nm. In another embodiment, the composition is in the form of nanofibers having a diameter in the range of 30-175 nm. In yet another embodiment, the composition is in the form of nanofibers having a diameter in the range of 20-150 nm. In an alternative embodiment, the composition is in the form of nanofibers having a diameter in the range of 20-100 nm. In yet another embodiment, the composition is in the form of nanofibers having a diameter in the range of 20-80 nm.

[0061] In an embodiment of the present disclosure, a composition is provided, comprising: (a) a polyanionic component comprising casein or a derivative thereof; and (b) a polycationic component comprising chitosan or a derivative thereof, wherein the composition is in the form of nanofibers having a diameter in the range of 20-200 nm, and wherein the polyanionic component comprising casein or a derivative thereof has a casein content in the range of 20-80% by weight relative to the composition. In another embodiment, the polyanionic component comprising casein or a derivative thereof has a casein content in the range of 30-70% by weight relative to the composition.

[0062] In an embodiment of the present disclosure, a composition is provided, comprising: (a) a polyanionic component comprising casein or a derivative thereof; and (b) a polycationic component comprising chitosan or a derivative thereof, wherein the composition is in the form of nanofibers having a diameter in the range of 20-200 nm, and wherein the polycationic component comprising chitosan or a derivative thereof has a chitosan content in the range of 20-80% by weight relative to the composition. In another embodiment, the polycationic component comprising chitosan or a derivative thereof has a chitosan content in the range of 30-70% by weight relative to the composition.

[0063] In one embodiment of the present disclosure, a composition is provided, comprising: (a) a polyanionic component comprising casein or a derivative thereof; and (b) a polycationic component comprising chitosan or a derivative thereof, wherein the composition is in the form of nanofibers having a diameter in the range of 20-200 nm, and wherein the weight ratio of the polyanionic component comprising casein or a derivative thereof to the polycationic component comprising chitosan or a derivative thereof is 2:8 to 8:2. In another embodiment, the weight ratio of the polyanionic component comprising casein or a derivative thereof to the polycationic component comprising chitosan or a derivative thereof is in the range of 3:7 to 7:3.

[0064] In one embodiment of the present disclosure, a composition is provided, comprising: (a) a polyanionic component comprising casein or a derivative thereof; and (b) a polycationic component comprising chitosan or a derivative thereof, wherein the composition is in the form of nanofibers having a diameter in the range of 20-200 nm, and wherein the polyanionic component comprising casein or a derivative thereof further comprises at least one material selected from the group consisting of hyaluronic acid, alginate, dextran sulfate, carrageenan, chondroitin sulfate, pectin, polygalacturonic acid, xanthan gum, heparin, their derivatives, and combinations thereof.

[0065] In one embodiment of the present disclosure, a composition is provided, comprising: (a) a polyanionic component comprising casein or a derivative thereof; and (b) a polycationic component comprising chitosan or a derivative thereof, wherein the composition is in the form of nanofibers having a diameter in the range of 20-200 nm, and wherein the polycationic component comprising chitosan or a derivative thereof further comprises at least one material selected from the group consisting of gelatin, dextran, cyclodextrin, derivatives thereof, and combinations thereof.

[0066] In one embodiment of the present disclosure, there is provided a composition as described herein, wherein the polyanionic component comprising casein or a derivative thereof has casein in the range of 20-80% by weight relative to the composition, and the polycationic component comprising chitosan or a derivative thereof has chitosan in the range of 20-80% by weight relative to the composition, and the polyanionic component comprising casein or a derivative thereof further comprises at least one material selected from the group consisting of hyaluronic acid, alginate, dextran sulfate, carrageenan, chondroitin sulfate, pectin, polygalacturonic acid, xanthan gum, heparin, derivatives thereof, and combinations thereof, and the polycationic component comprising chitosan or a derivative thereof further comprises at least one material selected from the group consisting of gelatin, dextran, cyclodextrin, derivatives thereof, and combinations thereof.

[0067] In one embodiment of the present disclosure, a composition is provided, comprising: (a) a polyanionic component comprising casein or a derivative thereof; and (b) a polycationic component comprising chitosan or a derivative thereof, wherein the composition is in the form of nanofibers having a diameter in the range of 20-200 nm, and the composition further comprises at least one additive selected from the group consisting of antimicrobial agents, growth factors, debridements, antihistamines, anti-inflammatory agents, copper salts, silver salts, and combinations thereof.

[0068] In one embodiment of the present disclosure, a composition is provided, the composition comprising: (a) a polyanionic component comprising casein or a derivative thereof; and (b) a polycationic component comprising chitosan or a derivative thereof, wherein the composition is in the form of nanofibers having a diameter in the range of 20-200 nm, and the composition further comprises at least one additive selected from the group consisting of: human serum albumin, bovine thrombin, calcium, human thrombin (h-thrombin), rh-thrombin, factor XIII, factor VIIa, recombinant factor XIII (r-factor XIII), prostaglandin-2a, thromboxane A2, epidermal growth factor, tumor necrosis factor (TNF), platelet-derived growth factor, TNF-α, transforming growth factor (TGF), von Willebrand factor, TGF-α, TGF-β, -β, fibroblast growth factor, nerve growth factor, insulin-like growth factor, keratinocyte growth factor, penicillin, methicillin, ampicillin, amoxicillin, clavulanic acid, clavamox, aztreonam, streptomycin, imipenem, kanamycin, bacitracin, tobramycin, vancomycin, polymyxin, gentamicin, clindamycin, erythromycin, amphotericin, rifampicin, nystatin, tetracycline, doxycycline, doxycycline, chloramphenicol, fibrin, thrombin, ascorbic acid, rutin, tranexamic acid, licorice extract, thyme extract, galangal extract, grape extract and nettle extract, African bignonia (leaf) extract, Senegalese sweet apple (leaf) extract, heart leaf vine (aerial part) extract, rootless vine (aerial part) extract, and their combinations.

[0069] In one embodiment of the present disclosure, there is provided a method for preparing a composition comprising: (i) a polyanionic component comprising casein or a derivative thereof; and (ii) a polycationic component comprising chitosan or a derivative thereof, wherein the composition is in the form of nanofibers having a diameter in the range of 20-200 nm, the method comprising: (a) contacting a first aqueous solution of the polyanionic component comprising casein or a derivative thereof with a second aqueous solution of the polycationic component comprising chitosan or a derivative thereof to obtain an aqueous mixture; (b) treating the aqueous mixture to obtain suspended particles; (c) contacting the suspended particles with a desolvating agent to obtain a suspension; and (d) drying the suspension to obtain the composition.

[0070] In one embodiment of the present disclosure, a method for preparing a composition as described herein is provided, wherein the first aqueous solution comprises casein in the range of 0.5-4% w / v relative to the first aqueous solution, and the second aqueous solution comprises chitosan in the range of 0.5-3.5% w / v relative to the second aqueous solution. In another embodiment, the first aqueous solution comprises casein in the range of 1-3.5% w / v relative to the first aqueous solution, and the second aqueous solution comprises chitosan in the range of 1-3% w / v relative to the second aqueous solution.

[0071] In one embodiment of the present disclosure, there is provided a method for preparing the composition as described herein, wherein the desolvating agent is selected from the group consisting of tert-butyl alcohol, ethanol, acetone, and combinations thereof.

[0072] In one embodiment of the present disclosure, there is provided a method of preparing a composition as described herein, wherein the first aqueous solution and the second aqueous solution are prepared in water.

[0073] In one embodiment of the present invention, there is provided a method of preparing a composition as described herein, wherein the pH of the suspended particles is in the range of 4 to 10.

[0074] In one embodiment of the present invention there is provided a method of preparing a composition as described herein, wherein processing the aqueous mixture comprises a homogenisation step.

[0075] In one embodiment of the present disclosure, a method for preparing a composition as described herein is provided, wherein contacting a first aqueous solution comprising a polyanionic component of casein or a derivative thereof with a second aqueous solution comprising a polycationic component of chitosan or a derivative thereof is performed dropwise.

[0076] In one embodiment of the present disclosure, a method for preparing a composition as described herein is provided, wherein the polyanionic component comprising casein or a derivative thereof further comprises at least one material selected from the group consisting of hyaluronic acid, alginate, dextran sulfate, carrageenan, chondroitin sulfate, pectin, polygalacturonic acid, xanthan gum, heparin, derivatives thereof, and combinations thereof, and the polycationic component comprising chitosan or a derivative thereof further comprises at least one material selected from the group consisting of gelatin, dextran, cyclodextrin, derivatives thereof, and combinations thereof.

[0077] In one embodiment of the present disclosure, a method for preparing a composition as described herein is provided, wherein the method further comprises adding at least one additive selected from the group consisting of antimicrobial agents, growth factors, debridements, antihistamines, anti-inflammatory agents, copper salts, silver salts, and combinations thereof.

[0078] In one embodiment of the present disclosure, a method for preparing a composition as described herein is provided, wherein the method further comprises adding at least one additive selected from the group consisting of human serum albumin, bovine thrombin, calcium, human thrombin (h-thrombin), rh-thrombin, factor XIII, factor VIIa, recombinant factor XIII (r-factor XIII), prostaglandin-2a, thromboxane A2, epidermal growth factor, tumor necrosis factor (TNF), platelet-derived growth factor, TNF-α, transforming growth factor (TGF), von Willebrand factor, TGF-α, TGF-β, fibroblast growth factor, nerve growth factor, insulin-like growth factor, keratinocyte growth factor, fibroblast growth factor, and fibroblast growth factor. Factor, penicillin, methicillin, ampicillin, amoxicillin, clavulanic acid, clavamox, aztreonam, streptomycin, imipenem, kanamycin, bacitracin, tobramycin, vancomycin, polymyxin, gentamicin, clindamycin, erythromycin, amphotericin, rifampicin, nystatin, tetracycline, doxycycline, doxycycline, chloramphenicol, fibrin, thrombin, ascorbic acid, rutin, tranexamic acid, licorice extract, thyme extract, galangal extract, grape extract and nettle extract, African bignonia (leaf) extract, Senegalese sweet apple (leaf) extract, heart leaf vine (aerial part) extract, rootless vine (aerial part) extract, and their combinations.

[0079] In one embodiment of the present disclosure, there is provided a hemostatic product comprising a composition comprising: (a) a polyanionic component comprising casein or a derivative thereof; and (b) a polycationic component comprising chitosan or a derivative thereof, wherein the composition is in the form of nanofibers having a diameter in the range of 20-200 nm. In another embodiment, the hemostatic product is in a form selected from the group consisting of a bandage, a spray, a powder, a paste, and a foam.

[0080] In one embodiment of the present invention, a method for inhibiting blood loss from a bleeding site is provided, the method comprising: (a) obtaining a composition as described herein or a hemostatic product as described herein; and (b) applying the composition or the hemostatic product to a bleeding site to inhibit blood loss from the bleeding site.

[0081] In one embodiment of the present invention, a method of inhibiting blood loss from a bleeding site is provided, the method comprising: (a) obtaining a composition as described herein or a hemostatic product as described herein; and (b) applying the composition or the hemostatic product to a bleeding site to inhibit blood loss from the bleeding site, wherein the composition inhibits blood loss within less than 50 seconds after application. In another embodiment, the composition inhibits blood loss within 12-30 seconds of application.

[0082] In one embodiment of the present invention, a method of inhibiting blood loss from a bleeding site is provided, the method comprising: (a) obtaining a composition as described herein; and (b) applying the composition to a bleeding site to inhibit blood loss from the bleeding site.

[0083] In one embodiment of the present disclosure, a method of inhibiting blood loss from a bleeding site is provided, the method comprising: (a) obtaining a hemostatic product as described herein; and (b) applying the hemostatic product to a bleeding site to inhibit blood loss from the bleeding site.

[0084] In one embodiment of the present disclosure, there is provided a use of the composition for inhibiting blood loss from a bleeding site, the composition comprising: (i) a polyanionic component comprising casein or a derivative thereof; and (ii) a polycationic component comprising chitosan or a derivative thereof, wherein the composition is in the form of nanofibers having a diameter in the range of 20-200 nm.

[0085] In one embodiment of the present disclosure, there is provided a hemostatic article comprising a composition for inhibiting blood loss from a bleeding site, the composition comprising: (i) a polyanionic component comprising casein or a derivative thereof; and (ii) a polycationic component comprising chitosan or a derivative thereof, wherein the composition is in the form of nanofibers having a diameter in the range of 20-200 nm.

[0086] Although the subject matter has been described with reference to specific embodiments, such description is not meant to be construed in a limiting sense. Various modifications of the disclosed embodiments, as well as alternative embodiments of the subject matter, will become apparent to those skilled in the art upon reference to the description of the subject matter. It is therefore contemplated that such modifications may be made without departing from the spirit or scope of the subject matter as defined.

[0087] Example

[0088] The disclosure will now be illustrated using working examples, which are intended to illustrate the work of the disclosure, and are not intended to restrictively imply any limitation to the scope of the disclosure. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art to which the disclosure belongs. Although methods and materials similar or equivalent to the methods and materials described herein can be used to practice the disclosed methods and compositions, exemplary methods, devices and materials are described herein. It should be understood that the disclosure is not limited to the specific methods and experimental conditions described, because such methods and conditions may be applicable.

[0089] This section illustrates various embodiments of the present disclosure. It specifically provides advantages of the embodiments.

[0090] Example 1

[0091] Preparation of the compositions disclosed in the present disclosure

[0092] Chitosan (polycationic component) and casein (polyanionic component) are used to prepare the compositions disclosed in the present disclosure. Chitosan (>75% deacetylated, molecular weight 3800-20000 gmol -1 ) and casein (molecular weight is 4,23,644 gmol -1 ) was obtained from Himedia Laboratories. A chitosan solution of 0.5% (w / v) to 3.5% (w / v) (second aqueous solution) was prepared in water, and a casein solution of 0.5% (w / v) to 4% (w / v) (first aqueous solution) was prepared in water. The second aqueous solution was then added to the first aqueous solution to obtain an aqueous mixture. For experimental purposes, three mixtures of different ratios were prepared. The prepared samples are referred to as: CA30CH70 (casein:chitosan at a weight ratio of 30:70); CA50CH50 (casein:chitosan at a weight ratio of 50:50); and CA70CH30 (casein:chitosan at a weight ratio of 70:30). The details of the three compositions of the above samples are described in Table 1 below.

[0093] The aqueous mixtures obtained for three different ratios are processed independently. The processing involves a homogenization process and the pH is adjusted in the range between 6-10 to obtain suspended particles. The suspended particles are washed with alcohol in a repeated manner to ensure that there are no water molecules in the particles. The particles are further dissolved in a desolvating agent (or any liquid with a boiling point lower than water) to obtain a suspension. In order to dry the suspension, a manual drying process is adopted. The suspension is sprayed on a hot plate or heated aluminum foil (50° C.-80° C.) in a well-ventilated area to dry the suspension. After the drying step, the composition disclosed in the present disclosure in the form of a powder is obtained, which can be collected in a test tube for further research and / or application. The fragments of the composition are further made finer by using a vibrator. The disclosed method results in obtaining a composition in three different sample forms; sample 1 (CA30CH70), sample 2 (CA50CH50) and sample 3 (CA70CH30) as depicted in Table 1. Figure 1 Methods for obtaining compositions according to the present disclosure are summarized in .

[0094] As part of the present disclosure, samples 4 to 6 were also prepared by adjusting certain steps mentioned in the above paragraphs. The same process steps were followed until the steps of obtaining suspended particles in different samples, as described in Table 1, with different ratios of chitosan and casein. The suspended particles were not washed with ethanol and were subsequently insoluble in any desolvating agent. The suspended particles were dried independently on a hot plate to obtain sample 4 (CA30CH70_film), sample 5 (CA50CH50_film) and sample 6 (CA70CH30_film). Samples 4 to 6 were in film form, while samples 1 to 3 were in fine powder form. Samples 4 to 6 consisted of films having a thickness of about 10 microns.

[0095] Table 1:

[0096]

[0097] Example 2

[0098] Field Emission Scanning Electron Microscope (FESEM) Imaging Studies

[0099] FESEM imaging of the different samples was performed in order to analyze the nanoscale structure of the compositions of Samples 1 to 3 obtained from Example 1. In the FESEM imaging, it was observed that all samples had a nanofibrous structure with a fiber diameter ranging from 20 nm to 200 nm. Figure 2 The nanofibrous structure of the composition as obtained herein is shown. Figure 2 A and Figure 2 B shows nanofibers of the composition represented by Sample 1 (CA30CH70). Figure 2 C and Figure 2 D shows nanofibers of the composition represented by Sample 2 (CA50CH50). Figure 2 E and Figure 2 F shows nanofibers of the composition represented by Sample 3 (CA70CH30). It can be concluded that all of Samples 1 to 3 exhibit nanofibers with diameters in the range of 20-200 nm in accordance with the present disclosure.

[0100] Example 3

[0101] Zeta potential analysis

[0102] Measurement of the zeta potential value provides measurable information regarding the charge present on the surface of the nanofibers of the composition. Figure 3The zeta potential of nanofibers of the compositions of different composition ratios described in Example 1 is shown. Sample 1 (nanofibers composed of 30% casein and 70% chitosan) showed a zeta potential of 11.39 ± 7.19 mV. This charge continued to decrease as the amount of chitosan in the PEC decreased. The PEC nanofibers composed of 70% casein showed a zeta potential of -14.83 ± 11.95 mV. Zeta potential measurements show that the surface charge of the nanofibers is related to the composition of the nanofibers. The surface charge increases with increasing chitosan concentration. Figure 3 The surface charges of sample 1 (CA30CH70), sample 2 (CA50CH50), and sample 3 (CA70CH30) are depicted.

[0103] Example 4

[0104] Whole blood coagulation assay

[0105] The blood clotting ability of the composition described in Example 1 (samples 1 to 6) was measured by whole blood clotting assay. 200 μL of blood was placed in a microcentrifuge tube (Eppendorf tube), and 20 μL of 0.2M calcium chloride solution and the corresponding sample were added thereto at the same time. This process was repeated for each sample in the sample. The blood was ensured to coagulate by shaking the test tube to see if there was any movement of the blood, and the time was recorded. For comparison with the samples, Celox TM For reference, the corresponding clotting times of different samples are mentioned in Table 2.

[0106] Table 2:

[0107]

[0108] It can be observed from Table 2 that compared with the commercial product (Celox TM ). Samples 1 to 3 showed shorter clotting times compared to samples 4 to 6 (189 seconds, 212 seconds, 233 seconds), respectively. In addition, samples 1 to 3 also showed shorter clotting times of 15 seconds, 14 seconds and 13 seconds, respectively, compared to samples 4 to 6 (189 seconds, 212 seconds, 233 seconds), wherein samples 4 to 6 were in the form of membranes and had different processing steps as described in Example 1. Therefore, it can be understood that the nanofiber morphology of samples 1 to 3 (as shown in Example 2, the nanofiber diameter is in the range of 20-200) is crucial for obtaining shorter clotting times compared to samples 4 to 6 without nanofibers and in the form of membranes.

[0109] Example 5

[0110] Cell adhesion assay

[0111] To study the cell adhesion quality, samples 1 to 3 were used to clot blood samples as described in Example 4. After the whole blood sample formed a clot, the clotted sample was fixed by immersing it in formalin for 12 hours. After that, the fixed clot was taken out and immersed in tert-butyl alcohol for 12 hours. The sample was then dried in a vacuum desiccator. The clotted sample was then imaged by FESEM. Figure 4 FESEM imaging test results are shown.

[0112] Figure 4 Depicted are FE-SEM images of blood clots obtained using lower and higher magnifications for sample 1 - CA30CH70 (A, B), sample 2 - CA50CH50 (C, D), and sample 3 - CA70CH30 (E, F), respectively. These figures show that all samples promote cell adhesion regardless of the composition and surface charge of the sample.

[0113] Example 6

[0114] Lactate dehydrogenase (LDH) test

[0115] Platelet adhesion on the nanofiber surface of the compositions represented by samples 1 to 3 was quantified by the amount of LDH released upon cell lysis. The cells were lysed with a 1% tritonX100 solution. The concept behind this test is that every cell contains LDH, so the higher the LDH activity in the solution, the greater the number of platelets adhering to the fiber surface.

[0116] Figure 5 A graph showing the amount of LDH after performing the LDH test is depicted. Figure 5 ) can be clearly seen that samples 1 to 3 have significantly higher cell adhesion ability and a greater number of platelets are attached to the surface of the samples compared to the commercially available products. This may occur due to the surface charge of the samples. Surface charge plays an important role in cell adhesion because it affects platelets and plasma proteins. The charged surface also contributes to the formation of prothrombinase complexes (activated FV and FX) and intrinsic tenase complexes (activated F-VIII and F-IX), which lead to blood clots. Therefore, this embodiment once again demonstrates that the compositions of the present disclosure represented in the form of samples 1 to 3 are advantageous as hemostatic agents.

[0117] Example 7

[0118] Hemolysis assay

[0119] The hemolytic properties of samples 1 to 3 were performed to evaluate whether the samples were compatible with blood cells. In order to perform the test, a 0.9% NaCl solution was prepared. The anticoagulated blood was diluted by adding NaCl solution at a ratio of 4:5. Equal amounts of samples were placed in 15 ml polypropylene test tubes containing 6 ml NaCl solution and kept at 37°C for 30 minutes. After incubation, in each polypropylene test tube, 0.5 ml of diluted blood was added and kept at 37°C for 2 hours. Positive and negative controls were also prepared. The positive control was made by adding 6 ml NaCl solution, 0.5 ml of diluted blood and 0.01 M HCl solution. The negative control was made by adding 6 ml NaCl solution and 0.5 ml of diluted blood. After incubation for 2 hours, all samples were centrifuged at 2000 g for 20 minutes. Finally, the OD value of the supernatant at 540 nm was obtained. The test was performed in triplicate. The hemolysis percentage data of sample 1, sample 2 and sample 3 measured are mentioned in Table 3 below. With Celox TM All samples showed significantly lower hemolysis compared to the 1.2% and 1.5% saturation of ...

[0120] Table 3:

[0121] Sample No. Sample name Hemolysis (%) 1 CA30CH70 1.49±0.34 2 CA50CH50 1.82±0.13 3 CA70CH30 3.06±0.30 - <![CDATA[Celox TM ]]> 10.00±2.80

[0122] Example 8

[0123] Prothrombin time test

[0124] The prothrombin test (PT) is an indicator that shows whether a sample has any extrinsic pathway of the coagulation cascade. It indicates the duration of activation of the extrinsic pathway. A shortened PT indicates improved coagulation efficiency. This PT test may also be called an INR (International Normalized Ratio) test. This INR test actually standardizes the results obtained from the prothrombin time test, without taking into account the test method.

[0125] Prothrombin or F-II is one of the real-time clotting factors. The PT test is very important to check if the 5 different clotting factors (FI, F-II, FV, F-VII, and FX) are present in the blood and if they are working properly.

[0126] Generally, the PT value is between 2 and 3. If it is lower than 2, the PT value indicates that the blood has a high coagulation tendency, and if it is higher than 3, the PT value indicates that the blood has a delayed coagulation tendency. Figure 6Prothrombin tests of sample 1 (CA30CH70), sample 2 (CA50CH50), sample 3 (CA70CH30) and Celox are depicted. It can be observed that in the case of all samples 1 to 3, the values ​​of INR are between 2 and 3. Therefore, it can be understood that the composition of the present disclosure initiates clotting of blood in a natural manner.

[0127] Advantages of the present disclosure

[0128] The present disclosure discloses a composition comprising: a polyanionic component comprising casein or a derivative thereof; and a polycationic component comprising chitosan or a derivative thereof, wherein the composition is in the form of nanofibers having a diameter in the range of 20-200 nm. The composition described herein is fast acting and shows an almost instantaneous effect in inhibiting blood loss. As described in the assay, the composition shows a high level of blood clots. The composition is biodegradable and environmentally friendly. In addition, since biopolymers such as casein and chitosan are used, there are no significant side effects. The method for preparing the composition of the present disclosure is easy and scalable and provides high-throughput results.

Claims

1. A composition comprising: a) a polyanionic component comprising casein; and b) a polycationic component comprising chitosan, Wherein the composition is in the form of nanofibers having a diameter in the range of 20-100 nm, wherein the nanofibers are manufactured using self-assembly.

2. The composition according to claim 1, wherein The polyanionic component comprising casein has a casein percentage in the range of 20-80% by weight relative to the composition.

3. The composition according to claim 1, wherein The polycationic component comprising chitosan has a chitosan content ranging from 20 to 80% by weight relative to the composition.

4. The composition according to claim 1, wherein the weight ratio of the polyanionic component comprising casein to the polycationic component comprising chitosan or is in the range of 2:8 to 8:

2.

5. The composition of claim 1, wherein the polyanionic component comprising casein further comprises at least one material selected from the group consisting of hyaluronic acid, alginate, dextran sulfate, carrageenan, chondroitin sulfate, pectin, polygalacturonic acid, xanthan gum, heparin, and combinations thereof.

6. The composition of claim 1, wherein the polycationic component comprising chitosan further comprises at least one material selected from the group consisting of gelatin, dextran, cyclodextrin, and combinations thereof.

7. A method for preparing the composition according to claim 1, wherein the method comprises: a) contacting a first aqueous solution of a polyanionic component comprising casein with a second aqueous solution of a polycationic component comprising chitosan to obtain an aqueous mixture; b) treating the aqueous mixture to obtain suspended particles; c) contacting the suspended particles with a desolvating agent to obtain a suspension; as well as d) drying the suspension to obtain the composition.

8. The method according to claim 7, wherein the first aqueous solution comprises casein in the range of 0.5-4% w / v relative to the first aqueous solution, and the second aqueous solution comprises chitosan in the range of 0.5-3.5% w / v relative to the second aqueous solution.

9. The method of claim 7, wherein the desolvating agent is selected from the group consisting of tert-butyl alcohol, ethanol, acetone, and combinations thereof.

10. The method of claim 7, wherein the pH of the suspended particles is in the range of 4 to 10.

11. The composition according to claim 1, wherein the composition is used to inhibit blood loss from a bleeding site.

12. A hemostatic product comprising the composition according to claim 1.

13. The hemostatic article of claim 12, wherein the hemostatic article is in a form selected from the group consisting of a bandage, a spray, a powder, a paste, and a foam.

Citation Information

Patent Citations

  • Preparation and application of chitosan-based nano-fiber

    CN101280467A

  • Dissolvable nano web porous film and method of preparing the same

    CN102014962A

  • Chitosan-nanofiber hemostatic material and preparation method thereof

    CN103505758A

  • Bacterial cellulose-chitosan-laponite compound wound dressing and preparation method thereof

    CN107080856A

  • Natural fiber coated with chitosan and a method for producing the same

    US20030134120A1